Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning for Adult T Cell Leukemia/Lymphoma: Impact of Antithymocyte Globulin on Clinical Outcome  by Tanosaki, Ryuji et al.
Biology of Blood and Marrow Transplantation 14:702-708 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1406-0001$32.00/0
doi:10.1016/j.bbmt.2008.03.010Allogeneic Hematopoietic Stem Cell Transplantation
Using Reduced-Intensity Conditioning for Adult T Cell
Leukemia/Lymphoma: Impact of Antithymocyte
Globulin on Clinical Outcome
Ryuji Tanosaki,1 Naokuni Uike,2 Atae Utsunomiya,3 Yoshio Saburi,4 Masato Masuda,5 Masao Tomonaga,6
Tetsuya Eto,7 Michihiro Hidaka,8 Mine Harada,9 Ilseung Choi,2 Takeharu Yamanaka,10 Mari Kannagi,11
Masao Matsuoka,12 Jun Okamura10
1Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan; 2Department of Hematology,
National Kyushu Cancer Center, Fukuoka, Japan; 3Department of Hematology, Imamura Bun-in Hospital, Kagoshima,
Japan; 4Department of Hematology, Oita Prefectural Hospital, Oita, Japan; 5Cancer Center, University of the Ryukyus,
Okinawa, Japan; 6Department of Hematology, Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki
University, School of Medicine, Nagasaki, Japan; 7Department of Hematology, Hamanomachi Hospital, Fukuoka,
Japan; 8Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan;
9Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan;
10 Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan; 11Department of
Immunotherapeutics, Tokyo Medical and Dental University, Medical Research Division, Tokyo, Japan; and
12Laboratory of Virus Immunology, Institute for Virus Research, Kyoto University, Kyoto, Japan
Correspondence and reprint requests: Ryuji Tanosaki, MD, Stem Cell Transplantation Unit, National Cancer Center
Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan (e-mail: rtanosak@ncc.go.jp).
Received February 25, 2008; accepted March 25, 2008
ABSTRACT
Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for adult T cell leukemia/
lymphoma (ATLL), but shows high mortality. We evaluated the feasibility of reduced-intensity transplantation
using fludarabine and busulfan, with particular focus on the clinical impact of antithymocyte globulin (ATG) in
the conditioning regimen. Fourteen elderly patients with aggressive ATLL were enrolled in the current study
without ATG, and were compared to those in 15 patients who were treated similarly, but with ATG, in our pre-
vious study. Engraftment was prompt, and treatment was tolerable. Overall (OS) and progression-free survival
(PFS) at 3 years were 36% and 31%, respectively. HTVL-1 proviral load became undetectable by the polymerase
chain reaction in 62% of patients. Compared to the previous study with ATG, complete donor chimera was sig-
nificantly delayed. Although early relapse tended to be decreased, OS or PFS was not improved significantly.
Analysis of combined data from both our current and previous studies disclosed that grade I-II acute GVHD
was the only factor that favorably affected OS and PFS. These data suggested the presence of a graft-versus-
ATLL effect and the feasibility of a transplant procedure without ATG in elderly ATLL patients, but could
not demonstrate the clinical benefit of incorporating ATG.
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Adult T cell leukemia/lymphoma (ATLL) is a pe-
ripheral T cell malignancy that is associated with
human T cell leukemia virus type 1 (HTLV-1) and
a dismal prognosis [1]. It is classified into 4 subtypes702according to its clinical features: acute, lymphoma,
chronic, and smoldering. The former 2 subtypes have
the worst prognosis, with a median survival of approx-
imately 1 year [2-6]. On the other hand, recent reports
have suggested that about 40% to 45% of patients with
RIST for ATLL 703these subtypes could survive without disease after allo-
geneic hematopoietic stem cell transplantation (allo-
HSCT) using a conventional conditioning regimen
[7-10]. However, treatment-related mortality (TRM)
after conventional allo-HSCT is still as high as 40%
to 45% because most ATLL patients are over 50 years
of age and have poor morbidity, and this limits the
wider application of this procedure.
To overcome this limitation, we previously con-
ducted a phase I study of reduced-intensity allogeneic
transplantation (ATL-NST-1) to examine its feasibil-
ity and safety in the treatment of 15 patients with
ATLL who were aged 50 years or more [11]. The con-
ditioning regimen consisted of fludarabine (180 mg/
m2), busulfan (8 mg/kg), and low-dose (5 mg/kg) an-
tithymocyte globulin (ATG, Fresenius AG, Bad Hom-
burg, Germany), as modified from a previous report
[12]. Although this study confirmed its feasibility and
safety, 9 of the 15 patients (60%) relapsed, and 7 of
these relapsed within 100 days. This observed high
Table 1. Patient Characteristics in the Current Study in Comparison with
those in the Previous Study
ATG
2 1
Characteristic
Current Study
(ATL-NST-2)
Previous Study
(ATL-NST-1) P
Number of patients 14 15
Age, years .15
Median 56 57
Range 50-64 51-67
Patient sex 1.00
Male 9 8
Female 5 7
Subtype of ATLL 1.00
Acute 10 10
Lymphoma 4 5
Initial chemotherapy .65
CHOP-based 9 12
LSG 15 3 2
Modified EPOCH 2 2
Status at transplantation .59
CR 4 3
PR 10 10
Refractory 0 2
Donor HTLV-1 serology 1.00
Positive 7 7
Negative 7 8
CD341 cells infused,
x106/kg pt weight
.39
Median 3.6 4.5
Range 1.3-9.4 1.6-8.0
ATLL indicates adult T cell leukemia/lymphoma; CHOP, cyclo-
phosphamide (Cy); doxorubicin (DXR); vincristine (VCR); pred-
nisone (Pred); LSG 15, Cy, DXR, VCR, Pred, MCNU,
carboplatin (CBDCA), etoposide (VP-16); Modified EPOCH,
VP-16, VCR, Pred, CBDCA, DXR; CR, complete remission;
PR, partial remission; HTLV-1, human T cell leukemia virus
type-1; ATG, antithymocyte globulin.rate of early relapse raised the possibility that ATG,
which was used to enhance engraftment and suppress
a graft-versus-host reaction, may have negatively sup-
pressed a graft-versus-lymphoma effect to lead to the
high relapse rate. Alternatively, the rapid proliferation
of ATLL cells may outpace a developing donor-
derived anti-ATLL activity. Therefore, in the present
modified phase I study (ATL-NST-2), we eliminated
ATG from the original conditioning regimen to com-
pare the results with the previous study. Because
ATLL is a rare endemic hematologic malignancy, to
the best of our knowledge, these are the only on-going
prospective trials that focus on reduced-intensity allo-
HSCT for this disease [13].
PATIENTS AND METHODS
Patient and Donor Characteristics
Eligibility criteria for this study were identical to
those in the first trial. Briefly, patients with ATLL of
acute or lymphoma type [2], who were aged between
50 and 70 years, were eligible. Patients were required
to be in either complete remission (CR) or partial re-
mission (PR) at the time of registration, and to have
an HLA-identical sibling donor. Patients did not
have an active uncontrolled infection. Those who had
a past history of CNS invasion were included. Written
informed consent was obtained from all patients and
donors before enrollment into the study, which was
approved by the institutional review board of each par-
ticipating hospital.
For thismodified study, 14 patients were registered
between March 2003 and February 2006 at 7 institu-
tions. Their characteristics are given inTable 1 in com-
parison with those of the 15 patients treated in the first
study (ATL-NST-1), whowere enrolled betweenApril
2001 and November 2002 and treated with low-dose
(5 mg/kg) ATG.
Treatment
Donors received granulocyte-colony stimulating
factor (G-CSF) 5 mg/kg twice daily, beginning 4
days before leukapheresis and continuing until collec-
tions were complete. The conditioning regimen con-
sisted of fludarabine 30 mg/m2 per day infused over
30 minutes on days 28 to 23, and busulfan 1 mg/kg
orally every 6 hours for 4 times on days 26 and 25.
For prophylaxis of graft-versus-host disease
(GVHD), cyclosporine 3 mg/kg per day was infused
continuously starting on day21, and the dose was ad-
justed to between 250 and 400 ng/mL. The dose was
tapered after 50 days if there was no sign of acute
GVHD (aGVHD). G-CSF 5 mg/kg was administered
to recipients on day 6 and thereafter until the absolute
neutrophil count was .1  109/L for 2 consecutive
days.
704 R. Tanosaki et al.Study Endpoints
The primary objective of the study was to evaluate
feasibility and safety in terms of the achievement of
complete donor chimera before 91 days, defined as
90% or more peripheral blood mononuclear cells
(PBMNC) of donor origin, and the occurrence of
TRM within 100 days after transplantation. The de-
gree of donor-recipient chimerism in PBMNC,
CD3-positive or negative fraction, was examined after
14, 30, 60, and 90 days according to the previously pub-
lished method [14]. The day of sustained engraftment
was defined as the first of 3 consecutive days with the
absolute neutrophil count exceeding 0.5  109/L.
The secondary objectives were toxicities, occur-
rence of aGVHD and chronic GVHD (cGVHD),
overall (OS) and progression-free survival (PFS), and
HTLV-1 proviral load as a surrogate marker for
anti-HTLV-1 effect. Toxicities were graded using
the National Cancer Institute Common Toxicity Cri-
teria (version 3.0) [15]. Acute GVHD was diagnosed
and graded according to the standard criteria [16,17].
Chronic GVHD was assessed according to the stan-
dard criteria in patients who survived .100 days after
transplantation [18]. OS was defined as the duration
from transplantation to death from any cause. PFS
was defined as the duration from transplantation to
disease progression or death from any cause. The
HTLV-1 proviral load was estimated by taking blood
samples before and 1, 2, 3, 6, 12, 18, and 24 months
after transplantation, and HTLV-1 proviral DNA
was measured by quantitative PCR amplification of
HTLV-1 pX DNA using a Light Cycler System.
The detection limit of the HTLV-1 proviral load
was 0.5 copies/1000 cells [19].
Statistical Analysis
We hypothesized that 80% of patients were ex-
pected to survive .100 days with engraftment of
90% or more of donor chimerism after this modified
treatment. Simon’s 2-stage design was used [20]. In
the first stage, 7 patients were to be assessed and we ex-
pected that.3 patients would fulfill the criteria. Next,
9 additional patients were to be assessed. If.10 of the
total 16 patients met the criteria, we considered that
our hypothesis would have been shown to be true.
Patients and disease characteristics were compared
by either Fisher’s exact test or the Wilcoxon rank-sum
test. Estimates of time to event, including neutrophil
recovery, complete donor chimera, death, relapse,
and GVHD, were made by the Kaplan-Meier method.
All P values are reported as 2-sided, with P\.05 indi-
cating statistical significance. The hazard ratio of death
or relapse with respect to clinical features was esti-
mated by a Cox proportional hazard model. All analy-
ses were performed using SPSS 15.0 or SAS (ver. 9) for
Windows.RESULTS
Engraftment and Toxicities
Because 12 of the 14 patients (86%) survived.100
days with complete donor chimera after transplanta-
tion, this treatment was demonstrated to be successful,
and the enrollment of patients was stopped at that
point. Neutrophil engraftment and complete donor
chimera in PBMNC were achieved in all 14 patients
before 91 days. The median number of days until en-
graftment and the achievement of complete donor chi-
mera was 11 days (range: 9 to 16 days) and 60 days (14
to 90 days), respectively. TRM occurred in 3 patients;
1 subdural hemorrhage on day 21, 1 interstitial pneu-
monia syndrome on day 32, and 1 bronchiolitis oblit-
erans on day 630.
In comparison with the previous study, where
ATG was included in the preparatory regimen, com-
plete donor chimera was significantly delayed in
PBMNC (Figure 1; P 5 .001) and CD3-positive T
cell fractions (P5 .038). On the other hand, the speed
of neutrophil recovery and the achievement of com-
plete donor chimera in CD3-negative myelomono-
cytic cell fraction were almost identical between the
2 studies.
Concerning nonhematologic toxicities, no patients
experienced grade 3 or 4 toxicities, except 3 TRM as
described above. CMV antigenemia was observed in
11 patients (79%) at least once within 100 days after
transplantation, although none developed a CMV
disease. Other infectious complications within 100
days after transplantation included mild hemorrhagic
Figure 1. Kaplan-Meier estimate of the cumulative probability of
achieving complete donor chimera in the mononuclear cell fraction
in peripheral blood. PBMNC indicates peripheral blood mononu-
clear cell; ATG, antithymocyte globulin; ATG(1), patients treated
with a conditioning regimen that included ATG in the previous
study (n 5 15); ATG(2), patients treated without ATG in the cur-
rent study (n 5 14). The achievement of complete donor chimera
was significantly delayed in the current study compared to the previ-
ous study (P 5 .001).
RIST for ATLL 705cystitis because of adenovirus in 3, and mild pneumo-
nia because of pseudomonas aeruginosa in 1 patient.
aGVHD and cGVHD
The incidence of aGVHDwas not significantly in-
creased in the current study (P5 .27); grade I to IVwas
86%, grade II to IV 57%, grade III to IV 21%, whereas
in the previous study these values were 67%, 60%, and
34%, respectively. Chronic GVHD developed in 10 of
12 patients (83%) who could be evaluated, and it
tended to be increased in the current study compared
to the previous study (Table 2; P 5 .063).
Relapse
Six patients relapsed (within 100 days in 3 [50%]).
Total and early relapse within 100 days tended to occur
less frequently in the current study than in the first
study, but these differences were not statistically signif-
icant (Figure 2A;P5 .26 and .25, respectively).Twopa-
tients relapsed in the CNS on days 78 and 778. Another
Table 2. Clinical Outcomes of the Current and the Previous Studies
ATG
2 1
Current Study
(n 5 14)
Previous Study
(n 5 15)
Characteristic No. % No. % P
Complete donor
chimera#90 days
14 100 14 93 .78
Death
Overall 8 57 10 67 .88
All TRM 3 21 4 27 .60
TRM #100 days 2 14 1 7 1.00
ATLL 5 36 6 40 .88
Relapse
Overall 6 43 9 60 .45
#100 days 3 21 7 47 .25
Acute GVHD 12 86 10 67 .27
I 4 29 1 7
II 5 36 4 27
III 3 21 3 20
IV 0 0 2 13
Chronic GVHD* 10/12 83 6/13 46 .063
CMV antigenemia 11 79 13 87 .65
EB-LPD 0 0 2 13
No. of pts with
undetectable
PCR for HTLV-1*†
8/13 62 8 53 .96
ATLL indicates adult T-cell leukemia/lymphoma; TRM, treat-
ment-related mortality; GVHD, graft-versus-host disease;
CMV, cytomegalovirus; EB-LPD, Epstein-Barr virus-associated
lymphoproliferative disorders; PCR, polymerase chain reactions;
HTLV-1, humanT cell leukemia virus type-1; ATG, antithymo-
cyte globulin.
*The number of evaluated patients is shown on the right side of the
slash in each column.
†The number of patients whose HTLV-1 provirus could not be
detected at lease once was counted.patient, who relapsed on the skin on day 30, responded
to withdrawal of cyclosporine and is currently alive
without disease 592 days after transplantation.
Kinetics of HTLV-1 Proviral Load
In 13 patients who could be examined serially for
HTLV-1 proviral load in the peripheral blood, this
value decreased after transplantation and reached an
undetectable level within 6 months in 8 patients
(62%), including 3 patients who were transplanted
from an HTLV-1 carrier donor. There was no signif-
icant difference in these kinetics between the 2 studies
(Table 2 and Figure 3). In 2 patients, it is still undetect-
able at 12 and 18 months after transplantation.
OSl and PFS
OS and PFS at 3 years were 36% (95% confidence
interval [CI], 21% to 51%) and 31% (95% CI, 17% to
Figure 2. Cumulative incidence estimates of relapse and Kaplan-
Meier survival estimates in comparison between the absence (the
current study) and presence (the previous study) of ATG in the con-
ditioning regimen. (A) Total and early relapse within 100 days
tended to be decreased in the current study, but not significantly dif-
ferent (P 5 .26). (B) There was no significant difference in overall
survival rate between with and without ATG (P 5 .28).
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Figure 3. The kinetics of the HTLV-1 proviral load within 6 months after RIST. The panel on the left (A) indicates the kinetics of HTLV-1
proviral load in the current study, whereas the panel on the right (B) shows the kinetics in the previous study. The HTLV-I proviral load was
expressed as copy numbers per 1000 mononuclear cells (MNC). A load of\0.5 copies per 1000MNCwas considered to be undetectable. Closed
circles indicate patients whose proviral load became undetectable at least once, whereas open circles indicate patients whose proviral load
remained detectable.45%), respectively, with a median follow-up time of
792 days (range: 592 to 1222 days) in surviving pa-
tients. There was no significant difference in OS
(Figure 2B; P 5 .49) or PFS (P 5 .28) between the 2
studies.
Factors that Affect OS and PFS in a Combined
Analysis of Both Studies
We examined the effects of various factors, includ-
ing the use of ATG in the conditioning regimen, age,
gender, type of ATLL, disease status at transplanta-
tion, donor’s HTLV-1 status, and aGVHD as
a time-dependent variable, on OS and PFS in a total
of 29 patients who had been enrolled into the 2 studies.
The Kaplan-Meier estimate revealed marked differ-
ences in OS and PFS among patients who were strati-
fied retrospectively according to the grade of aGVHD
(Figure 4). In a univariate analysis, only aGVHD of
grade I to II was identified as a prognostic factor
with a positive impact for both OS and PFS (Table
3). The use of low-dose ATG in the conditioning reg-
imen did not significantly influence OS or PFS in this
particular setting.
DISCUSSION
In our previous study, which incorporated low-
dose ATG, we showed that elderly patients with ag-
gressive ATLL could be transplanted safely, and that
laboratory-evaluated graft-versus-HTLV-1 activity
and clinically observed graft-versus-ATLL (GV-
ATLL) effect were important after allo-HSCT [11].
Nevertheless, disease relapse was the main cause of
treatment failure, and 9 of the 15 patients (60%) re-
lapsed, 7 of whom relapsed within 100 days after trans-plantation. The early relapse was considered to be
because of the highly resistant nature of ATLL. It
was speculated that the disease activity could not be
controlled by reduced-intensity conditioning therapy
per se, unless aGV-ATLL effect appears earlier. How-
ever, GVHD and a related GV-ATLL effect might
have been suppressed by ATG included in the condi-
tioning regimen.
In this modified phase I study, we again showed
that a reduced-intensity conditioning regimen, regard-
less of the use of ATG or not, was feasible and safe in
elderly patients with ATLL. Total and early relapse
within 100 days after transplantation tended to be de-
creased, although there were no significant differences,
as we had not expected. A univariate analysis also failed
to show any differences in OS or PFS between patients
in the 2 studies treated with and without ATG. It is
considered that the reason why we could not show
the impact of ATG was because of the small number
of patients in these cohorts and the relatively low
dose of ATG used in the previous study.
The speed of achieving complete donor chimera
was significantly delayed if ATG was not used in the
conditioning regimen, as has been reported [21]. It
was speculated that, without ATG, host T cells tended
to remain reactive to donor-derived allo-antigen and to
compete with donor cells in the early phase after trans-
plantation, and would require more time to be com-
pletely replaced by donor cells. Because the frequency
of aGVHD was not significantly different between
with and without ATG in the conditioning regimen,
the development of aGVHD may not be associated
with the achievement of complete donor chimera.
As shown here, there were no significant differ-
ences between the 2 study groups in most patients’
RIST for ATLL 707characteristics. Therefore, it is reasonable to analyze
rare patients in both studies combined together. In
the total of 29 patients included in both studies, the
median survival time was 304 days, and OS and PFS
at 3 years were 36% (95% CI, 27 to 45%) and 25%
(95% CI, 16 to 34%), respectively, with a median fol-
low-up of 1222 days (range: 592 to 1973) in the surviv-
ing patients. Moreover, our study revealed the
characteristics of ATLL in response to transplanta-
tion; despite the frequent occurrence of early relapse,
a significant number of patients survived thereafter.
Four patients who had a relapse subsequently re-
sponded to a rapid discontinuation of the immunosup-
pressive agent and had a sustained remission for 152,
562, 1498, and 1945 days after relapse, suggesting
that this disease entity is particularly susceptible to im-
mune modulation [22,23].
Patients who developed grade I-II aGVHD had
significantly better OS and PFS than other patients.
Because the development of severe GVHD is consid-
ered to be too toxic for ATLL patients who are elderly,
highly immune-compromised, and/or often have pre-
existing infectious complications, the regulation of im-
mune reaction should be important for controlling the
disease activity. We also confirmed that allogeneic
transplantation not only has an anti-ATLL effect,
but also anti-HTLV-1 activity. Eleven of the 14 pa-
tients (79%) who received graft from an HTLV-1-
negative donor and 5 of the 14 patients (36%) from
an HTLV-1-carrier donor became negative for
HTLV-1 proviral load in the peripheral blood at least
once within 6 months after transplantation, with no
meaningful difference between the 2 studies.
The frequency of infectious complications in our
studies was quite high, regardless of the use of ATG
in the conditioning regimen, because 24 of the total
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Figure 4. Kaplan-Meier estimate of overall survival for all patients
treated in both studies according to the grade of aGVHD. Patients
with grade I-II aGVHD had a significantly better overall survival
compared to those without aGVHD (P 5 .0012). Severe aGVHD
(grade III-IV) did not affect favorably in respect of overall survival
compared to those without aGVHD (P 5 .39).29 patients (83%) developed CMV antigenemia, al-
though all were successfully treated with gancyclovir
and none progressed to CMV disease. This high rate
may reflect profound immunodeficiency underlying
the process of ATLL, as has been reported [24,25].
Moreover, 2 patients developed EBV-lymphoprolifer-
ative disorders and both were in the first study: there
were none in the second study without ATG.
In conclusion, allogeneic reduced-intensityHSCT
using fludarabine and busulfan with or without low-
dose ATG was shown to be feasible and safe even in
elderly patients with ATLL, and the results suggested
that its efficacy may be because of a GV-ATLL effect.
A combined analysis suggests that the use of ATG
could provide too much immune suppression to pa-
tients who are already intensely immune-compro-
mised. To confirm these findings, a multicenter
phase II study of reduced-intensity HSCT using
fludarabine and busulfan without ATG is currently
underway.
Table 3. Univariate Analysis of Factors that Influence Overall and
Progression-Free Survival
Parameter and Group HR 95% CI P
OS
ATG
Absence versus presence 0.72 0.28 to 1.83 .49
Patient age
.55 versus #55 1.92 0.72 to 5.15 .19
Patient sex
Male versus female 0.67 0.26 to 1.71 .40
Subtype
Lymphoma versus acute 0.77 0.27 to 2.17 .61
Status at transplantation
PR versus CR 1.26 0.41 to 3.84 .69
Donor’s HTLV-1 status
Carrier versus noncarrier 1.15 0.46 to 2.91 .77
Acute GVHD
Grade I-II versus grade 0 0.07 0.01 to 0.35 .0012
Grade III-IV versus grade 0 0.59 0.17 to 2.00 .39
PFS
ATG
Absence versus presence 0.62 0.26 to 1.48 .28
Patient age
.55 versus #55 2.27 0.85 to 6.12 .10
Patient sex
Male versus female 0.81 0.32 to 2.07 .66
Subtype
Lymphoma versus acute 0.70 0.27 to 1.81 .46
Status at transplantation
PR versus CR 1.22 0.45 to 3.34 .70
Donor’s HTLV-1 status
Carrier versus noncarrier 1.06 0.45 to 2.49 .90
Acute GVHD
Grade I-II versus grade 0 0.15 0.05 to 0.49 .0014
Grade III-IV versus grade 0 0.39 0.13 to 1.13 .08
OS indicates overall survival; ATG, anti-thymocyte globulin; PR,
partial remission; CR, complete remission; HTLV-1, human T
cell leukemia virus type-1; GVHD, graft-versus-host disease;
PFS, progression-free survival; HR, hazard ratio.
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